Dechra Pharmaceuticals (DPH)

 

LSE:DPH: Annual Financial Report

Dechra Pharmaceuticals

19 Sep 2017 09:07:04

Dechra Pharm PLC

RNS Number : 1476R
Dechra Pharmaceuticals PLC
19 September 2017
 

 

 

 

Date: Tuesday, 19 September 2017

 

 

Dechra® Pharmaceuticals PLC

(the Company)

Annual Financial Report

 

 

The Company announced its Preliminary Results on 4 September 2017 in accordance with the financial reporting obligations of the Disclosure and Transparency Rules.

 

Copies of the Annual Report and Accounts for the year ended 30 June 2017, Notice of Annual General Meeting and Proxy Form have now been mailed to shareholders.

 

Copies of the Annual Report and Accounts and Notice of Annual General Meeting have also been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm.

 

The Annual Report and Accounts, Notice of Annual General Meeting and information relating to the voting rights of Shareholders (as required by section 311A of the Companies Act 2006) are available to view on the Company's website www.dechra.com. Further copies of the Annual Report and Accounts are available from the Company's registered office at:

 

24 Cheshire Avenue

Cheshire Business Park

Lostock Gralam

Northwich

CW9 7UA

 

 

 

Enquiries:

Melanie Hall, Company Secretary

Dechra Pharmaceuticals PLC

Tel: +44 (0) 1606 814730

 

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACSEAPNNFELXEEF